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Abstract
Background There is increasing interest in utilising novel
markers of cardiovascular disease risk in patients with chronic
heart failure (HF). Recently, it was shown that alpha-1-
antichymotrypsin (ACT), an acute-phase protein and major
inhibitor of cathpesin G, plays a role in the pathophysiology of
HF and may serve as a marker for myocardial distress.
Objective To assess whether ACT is independently associated
with long-term mortality in chronic HF patients.
Methods ACT plasma levels were categorised into quartiles.
Survival times were analysed using Kaplan-Meier curves and
Cox proportional hazards regression, without and with cor-
rection for clinically relevant risk factors, including sex, age,
duration of HF, kidney function (MDRD), ischaemic HF
aetiology and NT-proBNP.
Results Twenty healthy individuals and 224 patients (mean
age 71 years, 72 % male, median HF duration 1.6 years) with
chronic HF were included. In total, 159 (71 %) patients died.
The median survival time was 5.3 (95 % CI 4.5–6.1) years.
ACTwas significantly elevated in patients (median 433 μg/ml,
IQR 279–680) in comparisonwith controls (median 214μg/ml,
IQR 166–271; p<0.001). Cox regression analysis demonstrat-
ed that ACT was not independently related to long-term mor-
tality in chronic HF patients (crude HR=1.03, 95 % CI 0.75–
1.41, p=0.871; adjusted HR=1.12, 95 % CI 0.78–1.60, p=
0.552), which was confirmed by Kaplan-Meier curves.
Conclusion ACT levels are elevated in chronic HF patients,
but no independent association with long-term mortality can
be established.
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Introduction
Despite recent treatment advances, chronic heart failure (HF)
continues to impose a substantial healthcare burden. B-type
natriuretic peptide (BNP) and the biologically inactive N-
terminal fragment (NT-proBNP) are synthesised by ventricu-
lar myocytes in response to haemodynamic stress [1]. Natri-
uretic peptides (NPs) are useful in determining the diagnosis
and prognosis of congestive HF and their use is subsequently
advocated by the American College of Cardiology [2] and the
European Society of Cardiology guidelines [3]. However, NPs
have limitations that affect the interpretation of the results. Ele-
vated NP levels can also be seen in the setting of sepsis [4], acute
pulmonary embolism [5] and renal dysfunction [6]. NP levels are
higher in women than in men and increase with age [7]. More-
over, NP levels may be reduced in obese patients [8, 9]. Conse-
quently, novel biomarkers are currently under intensive investi-
gation and may be of help to improve the prognostication and
clinical outcome of HF patients. Recently, we proposed a role of
the acute-phase protein alpha-1-antichymotrypsin (ACT; also
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known as SERPINA3) in reverse remodelling [10]. Our previous
data demonstrated that high ACT plasma and myocardial levels
inHF decrease duringmechanical support. The goal of this study
was to evaluate the prognostic role of ACT levels with respect to
long-term mortality in chronic HF patients.
Methods and materials
Study population
Patient material consisted of plasma and data obtained from
the Deventer-Alkmaar Heart Failure study (DEAL-HF) [11, 12].
Briefly, 240 patients with typical signs and symptoms of HF
were included, combined with echocardiographic or radionu-
clide ventriculographic findings of a reduced left ventricular
systolic function (LVEF≤45 %) or diastolic dysfunction. The
main exclusion criteria were an expected survival of less than
1 year and planned hospitalisation. In the present study, a com-
plete set of data was available for 224 patients at baseline (due to
missing blood samples). Control plasma was collected from 20
anonymous healthy individuals. The study was approved by the
local Medical Ethics Committees and complied with the Decla-
ration of Helsinki. All patients gave written informed consent.
Laboratory assessment
Routine laboratory measurements and blood samples were
obtained at baseline. EDTA plasma was separated and stored
at minus 70 °C. Circulating levels of ACT were analysed
according to the description of the manufacturer (Genway
Biotech Inc, San Diego, USA). In short, the samples were
diluted 1:5000. Standards and samples were added in duplicate
in a 96-well plate coated with antibody and incubated. After
the first washing step, the conjugate was added, followed by
incubation. The next washing step was followed by the addi-
tion of the substrate solution and incubation. The stop solution
was added and wells were read out on a microplate reader.
Clinical follow-up
ACT values were assessed for all-cause mortality. Patients
were followed up to 10.5 years after randomisation at the
outpatient clinic. In case of no show, information regarding
survival was obtained from the hospital system, relatives or
general practitioner.
Statistics
Categorical data are presented by number (%) and numerical
data by mean±standard deviation or by median (interquartile
range, IQR, i.e. 25th–75th percentile), where appropriate. Com-
parisons between patients and healthy controls were performed
using independent-samples t-test or Mann-Whitey U-test for
numerical variables and Chi-square or Fisher’s exact test for
categorical variables. Linear regression analysis was performed
to assess clinically relevant factors independently related to ACT
plasma levels, such as sex, age, duration of HF, kidney function
(MDRD), ischaemic HF aetiology and NT-proBNP. Survival
times were analysed using Kaplan-Meier curves and Cox pro-
portional hazards (PH) regression, without and with correction
for the above-mentioned clinically relevant risk factors. Time to
event was defined as time between inclusion and death or to end
of study/loss to follow-up (censored). PH assumption was
checked using Schoenfeld residuals and linearity assumption
by adding and testing mean-centred quadratic terms. A p-value
≤0.05 was considered to be statistically significant. All analyses
were done with SPSS 20.0 software (SPSS Inc, Chicago, IL).
Results
Baseline characteristics
Characteristics of the study population are described in Table 1.
The study cohort consisted of patients with severe chronic HF
with a mean age of 71 years, 72 % were male with a median HF
duration of 1.6 years. Almost all patients (97 %) had left ventric-
ular systolic dysfunction with a reduced ejection fraction, the
mean ejection fraction being 31 %. At the time of inclusion,
ischaemic aetiology of HF was present in 146 patients (65 %).
Non-survivors were older, male subjects with a longer duration of
HF, higher C-reactive protein and NT-proBNP levels, more often
had kidney dysfunction,weremore often diagnosedwith diabetes
mellitus, anaemia and ischaemic heart disease andwere less often
treated with beta-blocking agents in comparison with survivors.
Plasma levels of ACT in patients and healthy controls
Figure 1 shows the plasma levels of ACT in patients and
healthy controls. A large individual variation of ACT was
found. ACT was significantly elevated in patients (median
433 μg/ml, IQR 279–680) in comparison with controls
(median 214 μg/ml, IQR 166–271; p<0.001). A linear
regression analysis showed that the duration of HF was inde-
pendently related to ACT plasma levels (patients with a shorter
duration of HF had a higher ACT plasma level; p=0.031).
Only 5.4 % of the variation in ACT plasma levels is explained
by the model (R-square=0.054), which means that the large
differences in ACT plasma levels between patients cannot be
explained by the variables included in the model.
ACT levels and mortality
The mean and median survival time was 5.5 and 5.3 years,
respectively. In total, 159 (71%) patients died. Cox-proportional
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hazard regression models showed that ACT plasma levels
(mg/ml) were not significantly related to long-term mortality
(crude HR=1.03, 95 % CI 0.75–1.41, p=0.871; adjusted
HR=1.12, 95 % CI 0.78–1.60, p=0.552). HR present the effect
of ACT per 1000 μg/ml=1 mg/ml. This non-significant effect
of ACT was also confirmed by the Kaplan-Meier curves pre-
sented in Fig. 2, where circulating ACT was divided into
quartiles and presented as Kaplan-Meier curves.
Discussion
In the present study, ACT levels were significantly elevated in
chronic HF patients in comparison with healthy controls and
demonstrated that a singlemeasurement of plasmaACT is not an
independent risk factor for long-term mortality in these patients.
Multiple microarray analyses have been conducted to
screen the gene expression profile of the failing myocardium
from patients with dilated cardiomyopathy and suggested
elevated ACT expression in the failing heart [13–16]. These
findings were corroborated by our previous work in a small
panel of severe end-stage HF patients who demonstrated
profound elevated ACT levels in heart tissue as well as plasma
at the time of left ventricular assist device implantation. The
present study aimed to verify ACT up-regulation in a larger
cohort of chronic HF patients.
ACT seems to be involved in the pathophysiology of HF.
The exact role of ACT in HF is unknown, but several effects
Table 1 Baseline characteristics
Variable Total Survivors Non-survivors p-value1
(n=224) (n=65) (n=159)
Age, years 71±10 67±11 72±9 0.001
Sex, male (%) 72 60 77 0.008
HF, ischaemic aetiology (%) 65 51 72 0.004
Duration of HF, years 1.6 (0.3–5.8) 0.4 (0.2–3.3) 2.6 (0.4–6.5) <0.001
NYHA class, III/IV (%) 99 98 99 0.986
Comorbidities
Diabetes (%) 30 20 33 0.047
COPD (%) 28 29 27 0.740
CVA (%) 10 8 11 0.417
Hypercholesterolaemia (%) 47 48 49 0.853
Anaemia (%) 17 8 20 0.023
Laboratory
Haemoglobin, mmol/l 8.4±1.0 8.6±0.8 8.3±1.0 0.135
Sodium, mmol/l 138±3 139±3 138±3 0.030
Potassium, mmol/l 4.4±0.5 4.4±0.4 4.4±0.5 0.446
Urea, mmol/l 11.0±5.4 9.6±4.1 11.6±5.8 0.005
Creatinine, μmol/l 127±36 115±23 131±40 <0.001
MDRD 52±14 55±13 51±15 0.086
Leukocytes, ×10^9/l 7.8±2.2 7.5±1.8 7.9±2.4 0.157
CRP, mg/l 8 (5–16) 6 (3–11) 10 (6–18) <0.001
NT-proBNP, pg/ml 2089 (973–4364) 1725 (727–3341) 2360 (1074–5776) 0.003
Medication use
ACE inhibitors (%) 88 91 87 0.419
ARBs (%) 16 17 15 0.711
Beta-blockers (%) 79 89 75 0.022
Calcium blockers (%) 7 8 6 0.769
Digoxin (%) 28 17 33 0.019
Diuretics (%) 99 98 99 0.988
Nitrates (%) 41 42 40 0.750
Values are presented as means±standard deviations, medians±interquartile ranges or as frequencies and percentages
HF heart failure, NYHA New York Heart Association, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, CRP C-reactive
protein, NT-proBNP N-terminal pro-brain natriuretic peptide, ACE angiotensin-converting enzyme, ARB angiotension receptor blocker
1 comparison survivors versus non-survivors
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on the cardiovascular system have been postulated. ACT is a
serine protease inhibitor, mainly of cathepsin G [17]. By
eliminating cathepsin G, ACT might prevent the degradation
of connective tissue proteins [18] and the activation of the
transforming growth factor pathway [19], with subsequently
less cardiomyocyte necrosis, hypertrophy and fibrosis. Also,
ACT is an acute-phase protein and induces tumour necrosis
factor (TNF)-α and NF-κB [20]. Additionally, ACT is thought
to be protective during ischaemia reperfusion by inhibiting
neutrophil accumulation into the ischaemic-reperfused myo-
cardium and by inactivating cytotoxic metabolites released
from neutrophils [21].
The present study demonstrated that ACT plasma levels
were elevated in chronic HF patients, suggesting that ACT
might be useful as a diagnostic marker in HF. Nevertheless,
the present Cox PH regression analyses demonstrated that
ACT is not an independent risk factor for long-term mortality
in these patients with severe chronic HF. Future studies with
plasma samples taken at different time points and taken from
patients with less severe HF are necessary to analyse the
potential role of ACT as a prognostic marker in HF.
Limitations
The number of patients after 10 years of follow-upwas small. As
a sensitivity analysis, data up to 5 years of follow-up were also
analysed with Cox regression, and showed similar results. Only
one random plasma sample per patient was available for the
present study. As a result, the possible effect of a change in levels
of ACT on mortality is unknown. In this study, mainly chronic
HF patients with an older age and reduced ejection fraction
(HFrEF) were included. Our results cannot be extrapolated to
young patients and/or less severe forms of HFrEF, acute HF and
HF with a preserved left ventricular systolic function (HFpEF).
Themain exclusion criteria, expected survival of less than 1 year
and planned hospitalisation, may have caused a selection bias,
since these patients are expected to have high ACT levels. The
endpoint of the present study was all-cause mortality. Therefore,
we are not informed about the relation between the novel marker
and hospitalisations for HF or other serious events.
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